Current Suspected Overdose Deaths in Delaware for 2024: Get Help Now!
Find school water testing results and additional resources
Attention Medicaid Participants: Eligibility Renewals Restarted April 1, 2023
The Delaware Division of Public Health (DPH) wishes to alert the medical community of changes in recommendations for the treatment of gonorrhea.
The CDC continues to see concerning patterns of decreased susceptibility to cephalosporins in the treatment of gonorrhea. On August 10, 2012 the Centers for Disease Control and Prevention (CDC) published its weekly MMWR August 10, 2012 / Vol. 61, “Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010” which stated oral cephalosporins are no longer a recommended treatment for gonococcal infections.
Data from CDC’s Gonococcal Isolate Surveillance Project (GISP), described laboratory evidence of declining cefixime susceptibility among urethral N. gonorrhea isolates collected in the United States during 2006–2011.
|
Updated Recommended Treatment Regimens for Gonococcal Infections |
|---|
|
Uncomplicated gonococcal infections of the cervix, urethra, and rectum Recommended regimen Ceftriaxone 250 mg in a single intramuscular dose PLUS Azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days* Alternative regimens If ceftriaxone is not available: Cefixime 400 mg in a single oral dose PLUS Azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days* PLUS Test-of-cure in 1 week (can only be tested by gonorrhea culture, not nucleic acid amplification test {NAAT}) If the patient has severe cephalosporin allergy: Azithromycin 2 g in a single oral dose PLUS Test-of-cure in 1 week (can only be tested by gonorrhea culture, not nucleic acid amplification test {NAAT}) Uncomplicated gonococcal infections of the pharynx Recommended regimen Ceftriaxone 250 mg in a single intramuscular dose PLUS Azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days* |
Health care providers need to be aware of the potential for future resistance and take these important steps to ensure successful treatment outcomes for their patients:
* Because of the high prevalence of tetracycline resistance among Gonococcal Isolate Surveillance Project isolates, particularly those with elevated minimum inhibitory concentrations to cefixime, the use of azithromycin as the second antimicrobial is preferred.
For additional information about this or any other STDs or to report a case, call the DPH Sexually Transmitted Disease Program at 302-744-1050 or visit our web page @ http://dhss.delaware.gov/dph/dpc/stds.html
********************
You are receiving this message because you are a registered member of the Delaware Health Alert Network. If you are not a member and would like to subscribe, please register at https://healthalertde.org
About the Department
Secretary's Letter
Secretary Bio
Newsroom
State Jobs
Calendar
Delaware Health Care Commission
DHSS Administration Contact
Federal COVID Funding Dashboard
Delaware's Governor
State Agencies
Elected Officials
General Assembly
Delaware Courts
State Employees
Cities & Towns
Delaware State Code
State Regulations
Business First Steps
Phone Directory
Locations Directory
Public Meetings
Voting & Elections
Transparency
Delaware Marketplace
Tax Center
Personal Income Tax
Privacy Policy
Weather & Travel
Contact Us
Corporations
Franchise Tax
Gross Receipts Tax
Withholding Tax
Delaware Topics
Help Center
Mobile Apps
E-mail / Text Alerts
Social Media
Built by the Government Information Center
©MMXVIII Delaware.gov
